Global Liver Diseases Therapeutics Market Is Expected to Reach USD 10.9 Billion Globally in 2018: Transparency Market Research
Transparency Market Research Report Add " Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressant) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018" to its database.
November 26, 2013 (Newswire.com) - According to the latest market report published by Transparency Market Research "Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressant) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018", the global liver diseases therapeutics market was worth USD 6.5 billion in 2011 and is expected to reach USD 10.9 billion in 2018, growing at a CAGR of 8.6% from 2012 to 2018. In the overall global market, anti-viral drugs are expected to create its lead position in terms of revenue generation by 2018. Anti-viral drugs will have a share of 32.7% of the global market followed by vaccines at 19.1% in 2018.
Browse the full report: http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html
The major drivers of the global liver disease therapeutics market are increasing aging population inducing chronic diseases such as hepatitis and liver cancer, increasing global prevalence of liver disorder, high unmet needs existing in liver cancer and increased vaccination in emerging economies. However side-effects and risks associated with the medication, strict FDA approval norms and other government regulations and availability of alternate treatment procedures may act as the barrier for this market. Strong pipeline drugs and consolidation opportunities in the healthcare industry will pose future growth prospect for this market.
Anti-viral drugs represent the largest market in the liver disease therapeutics, which is justified by the fact that many oral, direct-acting antiviral medications are in development phase for treating hepatitis C. Currently, anti-virals are only available for hepatitis B and C. However, many anti-viral hepatitis C pipeline drugs namely GS-7977 (Nucleoside/Nucleotide polymerase inhibitor), Daclatasvir (NS5a Inhibitor), Asunaprevir (Protease Inhibitor), Simeprevie (Protease Inhibitor), and Vaniprevir (Protease Inhibitor), are expected to accelerate this market in near future.
The major players in the liver diseases therapeutics market include Astellas Pharma Inc, Gilead Science Inc, Merck & Co., Bristol-Myers Squibb, Novartis, Pfizer and Roche. In 2011, Astellas was the market leader in the immunosuppressants drugs market for liver diseases followed by Pfizer. In liver disease vaccines market, GlaxoSmithKline Pharmaceuticals Limited (GSK) represented as the major market player with a share of 45% in 2011. Bristol Myers Squibb had the largest market share in anti-viral drugs market for liver diseases followed by Gilead science in 2011.
This research is specially designed to estimate and analyze the demand for liver diseases therapeutics in global market. The research provides an in-depth analysis of the product sales, drugs class wise trend analysis and the major player pertaining to this market. High level analysis of the mentioned drug class of global liver diseases therapeutics market is performed and the report provides detailed analysis, comprehensive historical data and statistically tested forecast of the drug classes thus covered. Detailed qualitative information is given for different liver diseases and the application of different drugs as the treatment and therapy option.
Categories: Exercise and Physical Fitness